Polycyclo Ring System Is Tricyclo-carbocyclic Patents (Class 514/325)
-
Patent number: 5672611Abstract: Novel compounds of Formula ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the Formula 1.0 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.Type: GrantFiled: May 22, 1995Date of Patent: September 30, 1997Assignee: Schering CorporationInventors: Ronald J. Doll, Alan K. Mallams, Adriano Afonso, Dinanath F. Rane, Randall R. Rossman, F. George Njoroge
-
Patent number: 5668129Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: March 27, 1996Date of Patent: September 16, 1997Assignee: Novo Nordisk A/SInventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
-
Patent number: 5656606Abstract: The present invention is directed to certain novel compounds identified as camphor derivatives of the general structural formula: ##STR1## wherein A, X, Y, R.sup.2a, R.sup.4, and R.sup.5 are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.Type: GrantFiled: February 17, 1995Date of Patent: August 12, 1997Assignee: Merck & Co., Inc.Inventors: Ravi Nargund, Arthur A. Patchett
-
Patent number: 5629324Abstract: Compounds of the invention have the following structure: ##STR1## for example ##STR2## These compounds inhibit thrombin and associated thrombosis.Type: GrantFiled: April 10, 1995Date of Patent: May 13, 1997Assignee: Merck & Co., Inc.Inventors: Joseph P. Vacca, William C. Lumma, Stephen F. Brady, Thomas J. Tucker
-
Patent number: 5610165Abstract: N-Acylpiperidines of general structure ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.Type: GrantFiled: February 17, 1994Date of Patent: March 11, 1997Assignee: Merck & Co., Inc.Inventors: Malcolm MacCoss, Sander G. Mills
-
Patent number: 5605917Abstract: A method is provided for treating dysmenorrhea (menstrual cramps) employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog thromboxane A.sub.2 receptor antagonist such as ifetroban, alone or in combination with a non-steroidal anti-inflammatory drug (NSAID).Type: GrantFiled: December 22, 1994Date of Patent: February 25, 1997Assignee: Bristol-Myers Squibb CompanyInventor: Martin L. Ogletree
-
Patent number: 5550123Abstract: A method of inhibiting bone prosthesis degeneration comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: August 22, 1994Date of Patent: August 27, 1996Assignee: Eli Lilly and CompanyInventor: George J. Cullinan
-
Patent number: 5550136Abstract: Compounds of formula I ##STR1## wherein X and Y are H or halo; R.sup.2 is: [structures Ia, Ib or Ic;] ##STR2## R.sup.3 is selected from unsubstituted or substituted alkyl, aryl or heteroaryl groups;R.sup.4 is selected from H or (C1-6)alkyl,and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disoders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropschiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective mount of a compound of formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 19, 1995Date of Patent: August 27, 1996Assignee: Zeneca LimitedInventors: Robert T. Jacobs, Cyrus J. Ohnmacht, Diane A. Trainor
-
Patent number: 5512575Abstract: Compounds of formula I or I', ##STR1## wherein X and Y are independently selected from hydrogen, halo, and (1-6C)alkoxy;R.sup.1 is selected from(A) (1-6C)alkyl;(B) phenyl and naphthyl or substituted versions thereof;(C) phenyl (1-3C)alkyl and naphthyl (1-3C) alkyl;(D) five- and six-membered heteroaryl rings;(E) heteroaryl (1-3C)alkyl and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I or I' and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I or I', or a pharmaceutically acceptable salt thereof are claimed. The invention also relates to novel processes for producing enantiomeric methanoanthracenyl sulfoxides.Type: GrantFiled: October 19, 1993Date of Patent: April 30, 1996Assignee: Zeneca LimitedInventors: Robert T. Jacobs, Michael T. Klimas, Cyrus J. Ohnmacht, Marc O. Terpko
-
Patent number: 5508280Abstract: This invention relates to novel derivatives of 5H-dibenzo (a,d)cycloheptenes, to the processes for their preparation, to their muscarinic receptor antagonist properties and to their end-use application for treating Parkinson's Disease, tardive dyskinesia, and motion sickness.Type: GrantFiled: January 30, 1995Date of Patent: April 16, 1996Assignee: Merrell Pharmaceuticals, Inc.Inventors: Marcel Hibert, Luc Van Hijfte, Mary Richards, Paul Moser
-
Patent number: 5464840Abstract: Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha. and methods for treating septic shock, inflammation, or allergic disease.Type: GrantFiled: December 6, 1993Date of Patent: November 7, 1995Assignee: Schering CorporationInventors: Pauline C. Ting, Daniel M. Solomon, Wing C. Tom
-
Patent number: 5439940Abstract: The invention relates to novel, pharmaceutically active benz[e]indene derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, further to the use of the said benz[e]indene derivatives in the treatment of certain diseases and in the preparation of pharmaceutical compositions suitable for the treatment of said diseases.The new benz[e]indene derivatives according to the invention correspond to the general formula ##STR1## wherein A represents a group of the formula alk-NR.sup.1 R.sup.2, wherein alk represents a C.sub.2-7 alkylene group optionally carrying a hydroxy substituent,R.sup.1 and R.sup.2 are independently hydrogen, C.sub.1-7 alkyl, C.sub.2-7 alkenyl, C.sub.2-7 alkynyl, mono(C.sub.1-7)alkylamino(C.sub.1-7)alkyl, di(C.sub.1-7)alkylamino(C.sub.1-7)alkyl or C.sub.3-7 cycloalkyl; orR.sup.1 and R.sup.Type: GrantFiled: October 28, 1993Date of Patent: August 8, 1995Assignee: EGIS Gyogyszergyar Rt.Inventors: Klara Reiter nee Eszes, Zoltan Budai, Tibor Mezei, Gabor Blasko, Gyula Simig, Istvan Gyertyan, Luiza Petocz, Marton Fekete, Katalin Szemeredi, Istvan Gacsalyi, Gabor Gigler, Ludmilla Rohacas nee Zamkovaja, Maria Szecsey nee Hegedus, Eniko Szirt nee Kiszelly
-
Patent number: 5439919Abstract: Arylglycinamide derivatives represented by a general formula (1) ##STR1## (wherein Ar denotes a phenyl group which may have 1 to 3 substituents or naphthyl group which may have 1 to 3 substituents, R.sub.1 and R.sub.4 denote identically or differently hydrogen atoms or lower alkyl groups with 1 to 3 carbon atoms, R.sub.2 denotes a lower alkyl group with 1 to 6 carbon atoms, cycloalkyl group with 3 to 6 carbon atoms, lower alkyl group with 1 to 4 carbon atoms which may have a phenyl group which may have 1 to 3 substituents, norbornyl group, adamantyl group or phenyl group which may have 1 to 3 substituents, R.sub.3 denotes a hydrogen atom or lower alkyl group with 1 to 6 carbon atoms or it may form a ring constituting alkylene together with R.sub.2, R.sub.5 denotes a lower alkyl group with 1 to 6 carbon atoms or cycloalkyl group with 5 or 6 carbon atoms, R.sub.6 denotes a hydrogen atom or lower alkyl group with 1 to 6 carbon atoms or it may form a ring constituting alkylene together with R.sub.Type: GrantFiled: July 20, 1993Date of Patent: August 8, 1995Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyuki Miyachi, Mitsuru Segawa, Emiko Tagami, Hideo Okubo
-
Patent number: 5436243Abstract: Potentiating agents inhibit the development of multidrug resistance, reduce drug-resistance in drug-resistant tumors, or sensitize tumors to antineoplastic drugs, thereby potentiating the effect of antineoplastic agents. The potentiating agents are aminoanthraquinones, preferably 1,4-bis(N-substituted) amino anthraquinones, and pharmaceutically acceptable salts thereof.Type: GrantFiled: November 17, 1993Date of Patent: July 25, 1995Assignees: Research Triangle Institute Duke University, Pharmaceuticals CorporationInventors: Clifford W. Sachs, Robert L. Fine, Lawrence M Ballas, R. Ivy Carroll, Robert Bell
-
Patent number: 5432168Abstract: Prostate cancer particularly hormone-unresponsive metastatic prostate cancer, is treated by cyclophosphamide or other normally substantially inactive agent. Potentiation of the anti-cancer activity and amelioration of cyclophosphamide-associated toxicity is achieved by an initial intravenous infusion of DPPE over an approximately one hour period prior to cyclophosphamide treatment.Type: GrantFiled: December 27, 1993Date of Patent: July 11, 1995Assignee: University of ManitobaInventor: Lorne J. Brandes
-
Patent number: 5424318Abstract: A novel piperidine derivative is defined by the formula (I), including a salt thereof, ##STR1## wherein R.sup.1 denotes anthraquinone, X denotes a group of the formula --(CH.sub.2).sub.n --, a group of the formula --O(CH.sub.2).sub.n --, a group of the formula --S(CH.sub.2).sub.n --, a group of the formula --NH(CH.sub.2).sub.n --, a group of the formula --SO.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR2## a group of the formula ##STR3## a group of the formula ##STR4## a group of the formula --CH.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR5## (in all the above formulas, n is an integer of 1 through 7 and R.sup.3 represents a lower alkyl group or a benzyl group), a group of the formula ##STR6## a group of the formula ##STR7## a group of the formula --O--CH.sub.2 CH.sub.2 CH.dbd.Type: GrantFiled: January 5, 1994Date of Patent: June 13, 1995Assignee: Eisai Co., Ltd.Inventors: Hachiro Sugimoto, Takaharu Nakamura, Yutaka Tsuchiya, Hiroyuki Sugumi, Kunizou Higurashi, Norio Karibe, Yoshiharu Yamanishi, Hiroo Ogura, Shin Araki, Atsuhiko Kubota, Michiko Ohtake, Kiyomi Tamatsu
-
Patent number: 5403848Abstract: Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine) for the treatment of non-ulcerative dyspepsia (NUD), more particularly NUD which is characterized by dysfunction of central 5-HT 1A receptors. Dysfunction of the central 5-HT 1A receptors can be diagnosed by an azaspirodecanedione-induced prolactin response which is distinguishable from that observed in a subject with peptic ulcer disease and/or inflammatory bowel disease. A suitable azaspirodecanedione for inducing the prolactin response is buspirone.Type: GrantFiled: December 28, 1993Date of Patent: April 4, 1995Assignee: Earlow LimitedInventors: Timothy G. Dinan, Paul W. N. Keeling
-
Patent number: 5385917Abstract: Carboxylic acid derivatives of the formula: ##STR1## are provided, which are useful for treatment of androgen dependent diseases.Type: GrantFiled: July 16, 1993Date of Patent: January 31, 1995Assignee: Mitsubishi Kasei CorporationInventors: Hiroaki Ueno, Masahiko Morioka, Fumiko Hatanaka
-
Patent number: 5348965Abstract: The invention relates to therapeutically active azaheterocyclic compounds and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.Type: GrantFiled: May 14, 1992Date of Patent: September 20, 1994Assignee: Novo Nordisk A/SInventors: Knud E. Andersen, Lars J. S. Knutsen, Per O. Sorensen, Behrend F. Lundt, Jesper Lau, Hans Petersen
-
Patent number: 5344835Abstract: According to the invention there is provided a compound of formula (I): R.sup.1 --O(CH.sub.2).sub.m A(CH.sub.2).sub.n XR or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is a group of formula (a or b) where Z is --(CH.sub.2).sub.2-, --CH.dbd.CH--, --CH.sub.2 --S-- or --CH.sub.2 --O--; R is a group of formula (c, d or Het) and A is a group of formula (e, f or g) in which the N atom is attached to the group (CH.sub.2)n; m is 1 or 2; n is an integer of from 1 to 4; p is 1, 2 or 3; R.sup.2 and R.sup.3 are each independently hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy-(C.sub.1 -C.sub.4 alkyl), hydroxy, C.sub.1 -C.sub.4 alkoxy, halo, trifluoromethyl, nitro, cyano, sulphamoyl, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), carboxy, --CO.sub.2 (C.sub.1 -C.sub.4 alkyl), --CH.sub.2).sub.q CONR.sup.4 R.sup.5, -- (CH.sub.2).sub.q OCONR.sup.4 R.sup.5, --CH.sub.2).sub.q NR.sup.6 R.sup.7 or --NHSO.sub.2 NH.sub.2 in which R.sup.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.Type: GrantFiled: July 2, 1992Date of Patent: September 6, 1994Assignee: Pfizer Inc.Inventors: David Alker, Peter E. Cross
-
Patent number: 5324738Abstract: Cyproheptadine (4-(5H-dibenzo[a,d] cyclohepten-5-ylidene)-1-methylpiperidine) for the treatment of non-ulcerative dyspepsia (NUD), more particularly NUD which is characterised by dysfunction of central 5-HT 1A receptors. Dysfunction of the central 5-HT 1A receptors can be diagnosed by an azaspirodecanedione-induced prolactin response which is distinguishable from that observed in a subject with peptic ulcer disease and/or inflammatory bowel disease. A suitable azaspirodecanedione for inducing the prolactin response is buspirone.Type: GrantFiled: September 18, 1990Date of Patent: June 28, 1994Assignee: Earlow LimitedInventors: Timothy G. Dinan, Paul W. N. Keeling
-
Patent number: 5302602Abstract: Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.Type: GrantFiled: May 18, 1992Date of Patent: April 12, 1994Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Etsuo Oshima, Hiroyuki Obase, Akira Karasawa, Kazuhiro Kubo, Ichiro Miki, Akio Ishii, Hidee Ishii, Kenji Ohmori
-
Patent number: 5276053Abstract: A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.Type: GrantFiled: October 6, 1992Date of Patent: January 4, 1994Assignee: Warner-Lambert CompanyInventor: Graham Johnson
-
Patent number: 5272159Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.Type: GrantFiled: December 17, 1991Date of Patent: December 21, 1993Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, David C. Remy
-
Patent number: 5231104Abstract: A series of novel 1-(phenethyl) and 1-(2-heteroarylethyl)-3-substituted piperidine derivatives have been prepared, including their pharmaceutically acceptable salts and various novel key intermediates therefor. The 3-substituent present in these compounds is an unsubstituted or substituted diphenylmethoxy group or a diphenylmethoxy-derived group, while the 1-substituent is unsubstituted or substituted phenethyl or 1-(2-heteroarylethyl) wherein the heteroaryl moiety is thienyl, pyridyl or pyrazinyl. These compounds in the form of both their racemates and 3R-isomers, are useful in therapy as smooth muscle muscarinic receptor antagonists and therefore, are of value in the treatment diseases associated with altered motility and/or smooth muscle tone.Type: GrantFiled: February 5, 1992Date of Patent: July 27, 1993Assignee: Pfizer Inc.Inventors: David Alker, Peter E. Cross, Robert M. Wallis
-
Patent number: 5231105Abstract: An ethylamine derivative of formula (I): ##STR1## wherein A represents a carbon atom or a nitrogen atom;B represents a substituted or unsubstituted aralkyl or aryl group;C represents hydrogen, alkyl, aralkyl, or aryl, each of which may optionally be substituted orC may optionally be bonded to A to form an alkylene bridge which is optionally substituted,Q represents a substituted or unsubstituted aryl group, said group optionally being substituted by hetero atom(s) or substituent(s) optionally containing hetero atom(s); andX represents an alkylene bridge having from 2 to 20 carbon atoms and is optionally substituted with groups which include hetero atoms with the non-hetero atom substituents optionally containing hetero atoms.Type: GrantFiled: May 22, 1989Date of Patent: July 27, 1993Assignee: Ajinomoto Co., Inc.Inventors: Masataka Shoji, Kozo Toyota, Chikahiko Eguchi, Ryota Yoshimoto, Yosikatsu Koyama, Hideki Domoto, Akira Kamimura
-
Patent number: 5229400Abstract: A piperidine derivative of general formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein ##STR2## is any of several specified aromatic-containing groups; X is selected from one of several hetero atom-containing groups or C.sub.Type: GrantFiled: October 4, 1991Date of Patent: July 20, 1993Assignee: Ajinomoto Co., Inc.Inventors: Akira Hirasawa, Masataka Shoji, Ryota Yoshimoto, Yuichi Gyotoku, Chikahiko Eguchi
-
Patent number: 5189065Abstract: The use of products of formula (I) is described, wherein X and Y represent hydrogen, hydroxy or alkoxy; and R.sub.1 and R.sub.2 represent H, alkyl, alkenyl or alkynyl, arylalkyl, acyl or R.sub.1 and R.sub.2 together with nitrogen form a heterocycle for preparing an antitumoral drug.Type: GrantFiled: October 17, 1991Date of Patent: February 23, 1993Assignee: Roussel UclafInventors: Jorg Czech, Hans H. Sedlacek, Lucien Nedelec, Jacques Guillaume, Christian Marchandeau
-
Patent number: 5180736Abstract: A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.Type: GrantFiled: May 17, 1991Date of Patent: January 19, 1993Assignee: Warner-Lambert CompanyInventor: Graham Johnson
-
Cyclophanes, pharmaceutical compositions containing these compounds and processes for preparing them
Patent number: 5147882Abstract: Cyclophanes of the general formula ##STR1## wherein X.sub.1, X.sub.2, A, R and R.sub.1 to R.sub.4 are as defined herein, the enantiomers, diastereomers and addition salts thereof and, more particularly, for pharmaceutical use, the physiologically acceptable addition salts thereof, which have pharmacological properties such as lowering blood pressure, dilating the coronary blood vessels and a mild heart rate lowering activity, pharmaceutical compositions which contain these compounds and processes for preparing them.Type: GrantFiled: March 28, 1991Date of Patent: September 15, 1992Assignee: Karl Thomae GmbHInventors: Manfred Psiorz, Volker Trach -
Patent number: 5141960Abstract: A class of tricyclic glycinamide derivatives is described having use in treatment of CNS dysfunctions such as epilepsy and convulsive disorders. Compounds of most interest are those of the formula ##STR1## wherein each of X and Y is hydrido; wherein Z is selected from methylene, ethylene, ethenylene, thiomethylene and thioethylene; and wherein each of R.sup.1, R.sup.2 and R.sup.3 is hydrido; or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: June 25, 1991Date of Patent: August 25, 1992Assignee: G. D. Searle & Co.Inventors: Alexis A. Cordi, Claude L. Gillet
-
Patent number: 5132313Abstract: The present invention relates to novel NMDA receptor antagonists and methods for their use. The present invention also provided pharmaceutical compositions comprising such NMDA receptor antagonists.Type: GrantFiled: October 26, 1989Date of Patent: July 21, 1992Assignee: University of PittsburghInventors: Alan P. Kozikowski, Yuan-Ping Pang
-
Patent number: 5120732Abstract: Substituted 3-aminosydnone imines of the formula I ##STR1## and their pharmacologically acceptable acid addition salts, in which A denotes, for example, --CH.sub.2 --,R.sup.1 denotes hydrogen or the radical --COR.sup.5,R.sup.2, R.sup.3 denote alkyl having 1 to 4 C atoms,R.sup.5 denotes, for example, an aliphatic radical having 1 to 4 C atoms,and methods for preparing such compounds by cyclization of a compound of the formula II ##STR2## and if desired subsequent acylation. The invention also includes formulations containing effective amounts of such compounds, and methods for administering same to patients for the control and prophylaxis of cardiovascular disorders.Type: GrantFiled: August 29, 1990Date of Patent: June 9, 1992Assignee: Cassella AktiengesellschaftInventors: Karl Schonafinger, Rudi Beyerle, Helmut Bohn, Melitta Just
-
Patent number: 5114951Abstract: Potentiating agents for combatting multiple drug resistance of susceptible tumor cells in a subject in need of such treatment are disclosed. The potentiating agents disclosed are triprolidine, cis-triprolidine, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 1989Date of Patent: May 19, 1992Assignee: Burroughs Wellcome CompanyInventor: Ann C. King
-
Patent number: 5114919Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.Type: GrantFiled: February 11, 1991Date of Patent: May 19, 1992Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, David C. Remy
-
Patent number: 5106856Abstract: There are disclosed various compounds of the formula below, ##STR1## where X is hydrogen, loweralkyl, loweralkoxy, hydroxy or nitro;Y is hydrogen or loweralkoxy; or alternatively, X and Y combined together form the group --OCH.sub.2 O-- in which case the positions of X and Y on the benzene ring moiety must be adjacent to each other;and Z is hydrogen, loweralkyl, loweralkoxy, hydroxy, halogen or nitro;which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.Type: GrantFiled: June 7, 1991Date of Patent: April 21, 1992Assignee: Hoechst-Roussel Pharmaceuticals Inc.Inventors: Raymond W. Kosley, Jr., Bettina Spahl
-
Patent number: 5100901Abstract: A cyclic amine compound is defined by the formula: ##STR1## in which J is indanyl, indanonyl, indenyl, indenonyl, indanedionyl, tetralonyl, benzosuberonyl, indanolyl or a divalent group thereof, K is phenyl, an arylalkyl or cynnamyl, B is --(CHR22) r--, R22 being H or methyl, --CO-- (CHR22)r--, .dbd.(CH--CH.dbd.CH)b--, .dbd.CH--(CH2)c-- or .dbd.(CH--CH)d.dbd. and the ring including T and Q is piperidine. The compound is useful to treat senile dementia.Type: GrantFiled: October 18, 1989Date of Patent: March 31, 1992Assignee: Eisai Co., Ltd.Inventors: Hachiro Sugimoto, Yutaka Tsuchiya, Kunizou Higurashi, Norio Karibe, Youichi Iimura, Atsushi Sasaki, Yoshiharu Yamanishi, Hiroo Ogura, Shin Araki, Takashi Kosasa, Atsuhiko Kubota, Michiko Kosasa, Kiyomi Yamatsu
-
Patent number: 5098916Abstract: Certain propanobicyclic amine compounds are described for treatment of CNS disorders such as psychotic disorders, convulsions, dystonia and cerebral ischemia. Compounds of particular interest are of the formula ##STR1## wherein each R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, phenalkyl, phenyl, alkoxy, phenoxy, phenalkoxy, alkoxyalkyl, halo, haloalkyl and hydroxyalkyl; wherein R.sup.3 and R.sup.4 may be taken together to form oxo;wherein each of R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, fluoroalkyl, cycloalkylalkyl, alkoxyalkyl, henalkyl and phenyl; wherein G within the nitrogen-containing cyclohetero moiety is selected from ##STR2## wherein R.sup.15 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenalkyl, alkoxyalkyl and hydroxyalkyl; wherein each of R.sup.16 and R.sup.Type: GrantFiled: March 29, 1990Date of Patent: March 24, 1992Assignee: G. D. Searle & Co.Inventors: Nancy M. Gray, Brian K. Cheng
-
Patent number: 5095022Abstract: A piperidine derivative represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or a lower alkyl group; X represents --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, or --CH.sub.2 O--; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an --A--O--B-- group wherein A and B are the same or different and each independently represented an alkylene group having 1 to 3 carbon atoms which may be optionally substituted with a lower alkyl group is disclosed. Also disclosed are a pharmacologically acceptable salt of a compound of formula (I), a method for preparation of a compound of formula (I), an antihistaminic and antiallergic agent comprising a compound of formula (I), a pharmaceutical composition comprising a compound of formula (I), and a method for the treatment of an allergic disease by administering a compound of formula (I).Type: GrantFiled: June 13, 1990Date of Patent: March 10, 1992Assignee: Hokuriku Pharmaceutical Co., Ltd.Inventors: Yasuo Ito, Hideo Kato, Eiichi Koshinaka, Nobuo Ogawa, Hiroyuki Nishino, Jun Sakaguchi
-
Patent number: 5089506Abstract: Certain ethanobicyclic amine compounds are described for treatment of CNS disorders such as psychotic disorders, convulsions, dystonia and cerebral ischemia. Compounds of particular interest are of the formula ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, phenalkyl, phenyl, alkoxy, phenoxy, phenalkoxy, alkoxyalkyl, halo, haloalkyl and hydroxyalkyl; wherein R.sup.3 and R.sup.4 may be taken together to form oxo;wherein each of R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, fluoroalkyl, cycloalkylalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein G within the nitrogen-containing cyclohetero moiety is selected from ##STR2## wherein R.sup.11 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenalkyl, alkoxyalkyl and hydroxyalkyl wherein each of R.sup.12 and R.sup.Type: GrantFiled: April 30, 1990Date of Patent: February 18, 1992Assignee: G. D. Searle & Co.Inventors: Nancy M. Gray, Brian K. Cheng
-
Patent number: 5089505Abstract: A series of novel 1-(phenethyl) and 1-(1-heteroarylethyl)-3-substituted piperidine derivatives have been prepared, including their pharmaceutically acceptable salts and various novel key intermediates therefor. The 3-substituent present in these compounds is an unsubstituted or substituted diphenylmethoxy group or a diphenylmethoxy-derived group, while the 1-substituent is unsubstituted or substituted phenethyl or 1-(2-heteroarylethyl) wherein the heteroaryl moiety is thienyl, pyridyl or pyrazinyl. These compounds in the form of both their racemates and 3R-isomers, are useful in therapy as smooth muscle muscarinic receptor antagonists and therefore, are of value in the treatment diseases associated with altered motility and/or smooth muscle tone. The most preferred compound is (3R)-diphenylmethoxy-1-(3,4-methylenedioxyphenethyl)piperidine. Methods for preparing these compounds from known starting materials are provided.Type: GrantFiled: July 6, 1989Date of Patent: February 18, 1992Assignee: Pfizer Inc.Inventors: David Alker, Peter E. Cross, Robert M. Wallis
-
Patent number: 5081129Abstract: Treatment of patients suffering from anemias such as anemias of chronic disorders or anemias resulting as toxic side effects of drugs, ionizing radiation or kidney dialysis by administration of a serotonin antagonist, such as cyproheptadine, the administration taking place once a day during the evening, preferably after sunset.Type: GrantFiled: September 10, 1990Date of Patent: January 14, 1992Inventors: Roman Rozencwaig, Bernard Grad
-
Patent number: 5071853Abstract: A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.Type: GrantFiled: February 27, 1990Date of Patent: December 10, 1991Inventors: Christopher F. Bigge, Sheryl J. Hays, Graham Johnson, Perry M. Novak, Daniel F. Ortwine
-
Patent number: 5064827Abstract: Compounds of the present invention, are represented by the general formula ##STR1## wherein R.sub.1 group which may be alkyl of from 1 to about 6 carbon atoms, alkenyl of from 2 to about 6 carbon atoms, alkynyl of from 2 to about 10 carbon atoms, alkoxy wherein the alkyl group contains from 1 to about 6 carbon atoms, halogen, acetamido, amino, nitro, alkylamino of from 1 to about 6 carbon atoms, hydroxy, hydroxyalkyl of from 1 to about 6 carbon atoms, cyano or arylalkoxy wherein the alkyl group contains from 1 to about 6 carbon atoms R.sub.2, R.sub.3 and R.sub.4 are hydrogen or hydroxyl groups or the combination of either hydrogen or hydroxyl groups; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NHCOR.sub.5, --NHCONR.sub.5 R.sub.6, or --NHCOOR.sub.5 wherein R.sub.5 and R.sub.Type: GrantFiled: August 23, 1990Date of Patent: November 12, 1991Assignee: Du Pont Merck Pharmaceutical CompanyInventors: Ghanshyam Patil, William L. Matier, Khuong H. X. Mai
-
Patent number: 5061703Abstract: A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms;whereinR.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl;whereinR.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group,or a pharmaceutically-acceptable salt thereof, is disclosed.Type: GrantFiled: April 11, 1990Date of Patent: October 29, 1991Assignee: Merz + Co. GmbH & Co.Inventors: Joachim Bormann, Markus R. Gold, Wolfgang Schatton
-
Patent number: 5051407Abstract: A method for treating a viral infection in a human or animal patient comprising administering to such patient an antivirally effective amount of a substituted hydroxypiperidine, namely a 2-hydroxymethylene-3,4,5-trihydroxypiperidine.Type: GrantFiled: October 19, 1988Date of Patent: September 24, 1991Assignee: Bayer AktiengesellschaftInventors: Horst Boshagen, Bodo Junge, Gunther Kinast, Matthias Schuller, Jurgen Stoltefuss, Arnold Paessens
-
Patent number: 5025019Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.Type: GrantFiled: November 20, 1989Date of Patent: June 18, 1991Assignee: Analgesic AssociatesInventors: Abraham Sunshine, Eugene M. Laska, Carole E. Siegel
-
Patent number: 5021426Abstract: Various 3-substituted cyproheptadine derivatives are useful in the treatment of infection by Plasmodium falciparum and in the treatment of malaria either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with antimalarial agents or compounds. Methods of treating malaria and methods of treating infection by Plasmodium falciparum are also described.Type: GrantFiled: February 26, 1990Date of Patent: June 4, 1991Assignee: Merck & Co., Inc.Inventors: John J. Baldwin, Gabriel F. Eilon, Paul A. Friedman, David C. Remy
-
Patent number: 5010072Abstract: Applicants have discovered that certain previously known lactamimide derivatives possess, as a class, valuable calcium channel blocking activity. By virtue of this calcium antagonism activity the compounds are antihypertensives and will have other activities associated with calcium antagonists.Type: GrantFiled: June 28, 1988Date of Patent: April 23, 1991Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Michael G. Palfreyman, Norbert L. Wiech, Hsien C. Cheng, John M. Kane
-
Patent number: 4996215Abstract: A new piperidine compound is pharmacologically effective for treatment of the arrythmia and is defined by the formula: ##STR1## in which R.sup.1 is a lower alkyl or a tolyl, R.sup.2 is hydrogen, hydroxyl, a lower alkoxy or a lower alkyl, R.sup.3 is hydrogen, a lower alkyl, a lower alkenyl, a cycloalkyl or a cycloalkylalkyl, X is --CO--, --CH.sub.2 -- or --CHOH--, g is an integer of 1 to 3, h is an integer of 1 to 3, Y is hydrogen, a lower alkyl, a lower alkenyl, cyano, --CH.sub.2 COOR, R being hydrogen or a lower alkyl, a cycloalkyl, a cycloalkylalkyl, ##STR2## l being 1 or 2, --A--B, A being --(CH.sub.2).sub.Type: GrantFiled: September 15, 1989Date of Patent: February 26, 1991Assignee: Eisai Co., Ltd.Inventors: Hitoshi Oinuma, Motosuke Yamanaka, Kazutoshi Miyake, Tomonori Hoshiko, Norio Minami, Tadao Shoji, Yoshiharu Daiku, Kohei Sawada, Kenichi Nomoto